Proscia

Proscia’s AI-powered platform, Concentriq Dx, facilitates precision medicine by providing applications that support pathologists with research and diagnosis of cancer. It also offers clinical insights to diagnostic laboratories and pharmaceutical companies. Precision medicine drug developers use the platform for biomarker analysis, patient stratification, and the creation of large repositories of data that aid the drug development process.

The Philadelphia-based firm provides a broad portfolio of AI applications including DermaAI, a melanoma detection solution, and Automated Quality Control (QC) for performing QC on images. Its Concentriq Dx platform was certified under In Vitro Diagnostic Regulation (IVDR) for use in primary diagnosis, enabling its use in the European diagnostic pathology market. In addition to the US, the firm has set up operations in Ireland and Spain. 

Key customers and partnerships 

As of June 2023, the firm’s user base included 10 large pharmaceutical companies, reference laboratories, and health systems. Proscia has also partnered with the Joint Pathology Center to digitize the latter’s human tissue repository of more than 55 million slides. In addition, the company has an original equipment manufacturing agreement with Siemens Healthineers. 

In March 2023 , the company signed a multi-year distribution agreement with life science company Agilent Technologies, to provide a digital system for diagnosing pathology. The company also announced that Concentriq for Research has been chosen by contract research organization (CRO) Altasciences to help its sponsors provide life-saving treatments to patients more quickly and Virscio to provide faster and more informed drug safety insights. 

In June 2023 , the company partnered with Mindpeak, an AI-powered software developer, to provide an improved diagnosis for cancer patients through integrated AI-powered workflows in pathology.

Funding and financials

The firm’s latest funding round took place in June 2022, where it raised USD 37 million in a Series C funding round. The funds were allocated toward further expediting the adoption of its pathology platform, launching new solutions, and introducing other third-party applications. The firm also planned to scale its operations by expanding its distribution partnerships as well as expanding its sales, marketing, and support teams.